2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 821

Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Abstract Number: 1409

Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance
Abstract Number: 1840

Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy
Abstract Number: 1877

Pregnancy Outcomes in SLE: Before and after
Abstract Number: 1908

Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
Abstract Number: 793

Preliminary Analysis of Histological Findings in Diagnosis of Giant Cell Arteritis Biopsy Positive Patients
Abstract Number: 2615

Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis
Abstract Number: 210

Preliminary Assessment of Predictive Validity of Cartilage Thickness MRI Biomarkers in Knee OA – the Fnih OA Biomarkers Consortium
Abstract Number: 2788

Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project
Abstract Number: 2293

Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Abstract Number: 252

Preliminary Validation of the Michigan Body Map
Abstract Number: 2670

Premature Delivery in Patients with Systemic Lupus Erythematosus
Abstract Number: 939

Prenatal Methyl-Rich Diet Decreases Inflammation in Collagen Induced Arthritis
Abstract Number: 1073

Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus
Abstract Number: 1404

Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].